ArticleOncology letters2025
Prognosis and influencing factors of patients with different lymph node statuses after pathological complete response to neoadjuvant chemoradiotherapy in rectal cancer.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neoadjuvant chemoradiotherapy (nCRT) has been shown to improve outcomes for patients with rectal cancer, but the impact of the lymph node status after achieving pathological complete response remains elusive. The present study aimed to assess the prognosis and influencing factors of patients with rectal cancer with different lymph node statuses after achieving a pathological complete response to nCRT. The clinical data of 203 patients enrolled from Hengshui People's Hospital and Hebei Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from January 2010 to December 2020 were retrospectively analyzed. These patients had undergone preoperative nCRT and were pathologically classified as 'tumor stage 0 and lymph node status 0 after neoadjuvant therapy' (ypT0N0) or 'tumor stage 0 and residual tumor in regional lymph nodes after neoadjuvant therapy' (ypT0N+) postoperatively. After surgery, patients were followed up to evaluate tumor recurrence, metastasis and survival, including disease-free survival (DFS) and overall survival (OS). Cox proportional hazards models were used to analyze factors affecting DFS and OS. Among the 203 patients included, there were 127 cases in the ypT0N0 group and 76 cases in the ypT0N+ group. The median follow-up time for the entire cohort was 56 months (range, 13-107 months). Furthermore, 72 patients (35.5%) experienced recurrence, including 53 cases (26.1%) of distant metastasis, 10 cases (4.9%) of local recurrence and 9 cases (4.4%) of both distant metastasis and local recurrence. The 5-year OS and DFS rates for all patients were 82.3 and 77.3%, respectively. The 5-year OS rates for the ypT0N0 and ypT0N+ groups were 96.1 and 59.2% (P<0.0001), respectively, and the 5-year DFS rates were 88.2 and 59.2% (P=0.0002), respectively. In addition, clinical tumor stage (cT)3-4, clinical lymph node stage (cN)+, elevated serum carcinoembryonic antigen (CEA) and postoperative pathology (ypT0N+) were independent risk factors affecting OS and DFS. In summary, the results of the present study indicate that patients with ypT0N0 rectal cancer can achieve a good long-term prognosis after nCRT. Notably, postoperative treatment and follow-up should be performed for patients with ypT0N+ and those with elevated pre-nCRT CEA, cT3-4 and cN+ stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.